Biovian has successfully raised a new debt package with Eurazeo, which will be used to refinance existing debt and to finance investment in GeneCity.
The new funding package is an important milestone in Biovian’s growth journey and will support Biovian in continuing its strong organic growth.
Biovian is pleased to report that the GeneCity facility expansion project is progressing as planned. The investment is a strategic move aimed at meeting the growing demand for high-quality biopharmaceutical manufacturing services and further solidifying Biovian’s position as a trusted partner in the biopharmaceutical industry. The new GeneCity facility expansion will encompass state-of-the-art technologies and increased clinical- and commercial scale production capacities for viral vectors. Together with Biovian’s existing manufacturing facility, the new premises will increase the total area up to 11 500 sqm (123 800 sqft). The additional space complements Biovian’s existing manufacturing facilities in the area and will enable Biovian to undertake larger-scale viral vector projects as well as microbial protein projects and concurrent manufacturing campaigns by increasing overall production capacity and flexibility. The new viral vector facility building has been started in Q3/2023 and facility is expected to be ready in 2025.
Antti Nieminen, CEO and co-founder: “This is an important milestone for Biovian and ensures that building and commissioning of the new facility will be progressing on time and as planned.”